KY
Therapeutic Areas
Astellas Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Xtandi (enzalutamide) | Prostate Cancer | Approved |
| Betmiga (mirabegron) | Overactive Bladder | Approved |
| Prograf (tacrolimus) | Immunosuppression | Approved |
| Vesicare (solifenacin) | Overactive Bladder | Approved |
| ASP2215 (gilteritinib) | Acute Myeloid Leukemia | Approved |
| ASP1929 | Solid Tumors | Phase 2 |
| ASP0367 | Urothelial Carcinoma | Phase 3 |
| ASP3652 | NASH | Phase 2 |
Leadership Team at Astellas Pharma
TT
Tadaaki Taniguchi
Executive Vice President and Chief Financial Officer
MY
Masao Yoshida
Executive Vice President
YS
Yoshitsugu Shitaka
Senior Vice President, Chief Medical Officer
TA
Takeshi Aramaki
Senior Vice President, Head of Development
AP
Adam Pearson
Senior Vice President, Head of Oncology Development